Here are 1-3 brief analogies for Replimune (REPL):

• Imagine a company like Moderna or BioNTech, but instead of developing mRNA vaccines, Replimune engineers viruses to activate the immune system specifically to fight cancer.
• They're a specialized cancer immunotherapy company, much like a Kite Pharma (known for CAR-T cell therapy), but Replimune uses engineered oncolytic viruses to turn the body's immune system against tumors.

• RP1: A selectively replicating version of herpes simplex virus 1 designed to activate the immune system against a range of solid tumors.
• RP2: An oncolytic immuno-gene therapy expressing an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response.
• RP3: An oncolytic immuno-gene therapy designed to express multiple immune-activating proteins that stimulate T cells.

Replimune Group, Inc. (REPL) is a clinical-stage biotechnology company focused on the development of oncolytic immuno-gene therapies. Its product candidates, including RP1, RP2, and RP3, are currently in various phases of clinical trials and have not yet received regulatory approval for commercial sale.

As such, Replimune does not currently have commercial products on the market and therefore does not have major customers in the traditional sense of selling therapies to other companies or individuals.

Sushil Patel, Chief Executive Officer

Sushil Patel was appointed CEO of Replimune effective April 1, 2024. He initially joined Replimune three years prior as Chief Commercial Officer and most recently served as Chief Strategy Officer. Dr. Patel brings over 20 years of experience in the biotech industry, with expertise in pre- and post-launch commercialization strategy and execution in both U.S. and global markets. He has been involved in more than eight product launches across various roles in marketing, sales, and franchise management. Before joining Replimune, Dr. Patel served as franchise head for lung, skin, and rare cancers at Genentech.

Emily Hill, Chief Financial Officer

Emily Hill was appointed Chief Financial Officer of Replimune in September 2023. She has over 15 years of experience in the biotechnology and life sciences industry, having held senior financial management and investor relations roles at various public biotechnology and pharmaceutical companies. Prior to Replimune, Ms. Hill was CFO of PTC Therapeutics, a commercial-stage biotech company, where she also headed Investor Relations. At PTC, she was significantly involved in the company's growth from a development-stage company to one with five products generating revenues approaching $1 billion. Before PTC Therapeutics, Ms. Hill was Director of Investor Relations at Warner Chilcott until its acquisition by Actavis for approximately $8.5 billion. She also served as Senior Manager of Investor Relations at Genzyme Corporation.

Philip Astley-Sparke, Executive Chairman of the Board

Philip Astley-Sparke is a co-founder of Replimune and transitioned from CEO to Executive Chairman of the Board of Directors effective April 1, 2024. He was previously the President and CEO of BioVex Inc., a company he relocated from the UK to the US in 2005. BioVex developed the first oncolytic therapy approved in the U.S. and Europe, and was acquired by Amgen for up to $1 billion in 2011. Following BioVex/Amgen, he served as President at uniQure, where he established their U.S. infrastructure, including a large gene therapy manufacturing facility, and later as Chairman. Mr. Astley-Sparke is also an Operating Partner at Forbion Capital and has served as Chairman of Oxyrane.

Robert Coffin, President and Chief Research & Development Officer

Robert Coffin, Ph.D., is a co-founder of Replimune. He previously served as the Chief Executive Officer of Replimune before transitioning to the role of President and Chief Research & Development Officer in January 2020. Dr. Coffin was a key member of the team from BioVex Inc., which developed Imlygic (T-VEC), the first FDA-approved oncolytic immunotherapy, and was acquired by Amgen.

Christopher Sarchi, Chief Commercial Officer

Christopher Sarchi serves as the Chief Commercial Officer at Replimune. In this role, he is responsible for market strategy and launch preparations for the company's product candidates.

The key risks to Replimune's business revolve primarily around the successful development and commercialization of its oncolytic immuno-gene therapies.

1. Clinical Trial Failure and Regulatory Approval Risks: As a biotechnology company with its product candidates (RP1, RP2, and RP3) primarily in Phase I/II clinical trials, Replimune faces significant inherent risks associated with drug development. The most critical risk is the uncertainty surrounding the timing and outcomes of its clinical trials and subsequent regulatory approvals. For instance, Replimune's lead product candidate, RP1, previously received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for advanced melanoma, citing inadequate trial design and concerns over data interpretation. While a resubmission has been accepted with a new PDUFA date of April 10, 2026, there remains a risk of further rejections or delays. Biotech companies often face lengthy, expensive, and uncertain regulatory processes, and a high percentage of clinical trials, particularly Phase II trials, fail to advance.
2. Financial Risk and Need for Additional Capital: Replimune is currently operating at a loss, burning through significant cash to fund its research and development (R&D) and clinical trials. While the company currently maintains net cash, its high cash burn rate suggests that it will likely need to raise additional capital in the future to sustain operations and continue its development programs. Delays in clinical trials or regulatory approvals, such as the initial setback for RP1, can further extend the period of cash burn and increase financial risk. Future capital raises could lead to the dilution of existing shareholders, especially if the company needs to issue new shares when its stock price is low.
3. Competition and Market Adoption: The biopharmaceutical industry, particularly the cancer treatment market, is highly competitive. Replimune's success depends not only on achieving regulatory approval but also on its ability to effectively commercialize its products and gain market adoption. Even if approved, factors such as the competitive landscape, pricing strategies, and reimbursement policies will play crucial roles in determining the commercial viability of Replimune's therapies. For example, RP1 has been noted to potentially face challenges due to its complex administration, narrow label, and unclear payer value, despite an unmet need in melanoma.

RP1

• Cutaneous Squamous Cell Carcinoma (CSCC): The global cutaneous squamous cell carcinoma treatment market is expected to reach $16.86 billion by 2027.
• Melanoma: The global melanoma market is expected to reach $8.9 billion by 2034. In the U.S., Replimune estimates approximately 13,000 patients progress on or after PD-1 treatment annually, with approximately 80% of these patients eligible for treatment with RP1.

RP2

• Metastatic Uveal Melanoma: null
• Hepatocellular Carcinoma (HCC): The global liver cancer drugs market is expected to reach $14.9 billion by 2031. RP2 targets second-line HCC patients, which represents approximately 31.4% of liver cancer patients who require second-line therapy.

RP3

• null

Here are the expected drivers of future revenue growth for Replimune (REPL) over the next 2-3 years:

1. Commercialization of RP1 in anti-PD-1 failed advanced melanoma: Replimune is preparing for the potential FDA approval and subsequent commercial launch of its lead product candidate, RP1 (vusolimogene oderparepvec), for patients with anti-PD-1 failed advanced melanoma. The Biologics License Application (BLA) for this indication was accepted for Priority Review by the FDA in January 2025, with a Prescription Drug User Fee Act (PDUFA) date set for July 22, 2025. The company has already completed late-cycle FDA interactions and manufacturing inspections, and has established a commercial organization, including customer-facing staff and patient support programs, in anticipation of market entry. Management estimates that approximately 13,000 U.S. patients annually who have progressed on PD-1 therapy could be eligible for RP1.
2. Commercialization of RP1 in cutaneous squamous cell carcinoma (CSCC): Replimune is actively pursuing other skin cancer indications for RP1. Topline data from the registration-directed CERPASS clinical trial, evaluating RP1 combined with Libtayo® (cemiplimab-rwlc) in CSCC, was expected in Q3 2023, with a Biologics License Application (BLA) submission projected for Q1 2024. The cutaneous squamous cell carcinoma treatment market is anticipated to reach $16.86 billion by 2027, representing a significant market opportunity for Replimune upon successful approval and launch.
3. Advancement and potential commercialization of pipeline candidates RP2 and RP3: Replimune's pipeline extends beyond RP1 to include RP2 and RP3, which are engineered with distinct cytokine or co-stimulatory transgenes to target various tumor types and immune environments. Phase 2 programs for RP2 and RP3 were expected to commence around mid-2023 in indications such as third-line colorectal cancer (CRC), first- and second-line hepatocellular carcinoma (HCC), and squamous cell carcinoma of the head and neck (SCCHN). Specifically, the REVEAL Phase 2/3 trial for RP2 in metastatic uveal melanoma is actively enrolling, with a transition to Phase 3 expected in Q1 2027. Progress in these programs and their eventual commercialization could provide additional revenue streams for the company.

Share Issuance

• Replimune conducted a public offering in November 2024, pricing 6,923,000 shares of common stock at $13.00 per share and pre-funded warrants for 3,846,184 shares at $12.9999 per warrant. The aggregate gross proceeds from this offering were approximately $140 million.
• The company received approximately $156.0 million from common equity issuance in Q3 2025 and $96.7 million in Q1 2025 through equity financing.
• Replimune saw $10.4 million in cash inflows from common equity issuance in Q3 2026.

Inbound Investments

• Replimune has received significant cash inflows from the sale/maturity of investments, with $101.8 million in Q3 2026, $95.4 million in Q2 2026, and $92.5 million in Q3 2025.

Capital Expenditures

• Replimune's capital expenditures were $6.7 million in fiscal year 2025.
• Capital expenditures in Q3 2026 were $135K.
• For the last 12 months, capital expenditures totaled -$5.35 million.